Literature DB >> 26406979

Clinical Evidence that Coagulation Activation Drives Cancer Progression--a Report of 2 Cases.

Minna Voigtlaender1, Katharina Holstein, Sven Leuenroth, Jonas Mudter, Carsten Bokemeyer, Florian Langer.   

Abstract

BACKGROUND: Tissue factor (TF), the principal initiator of the extrinsic coagulation pathway, is expressed by many tumors and can be released into the bloodstream on plasma microparticles (MPs). Experimental studies indicate that TF may facilitate hematogenous metastasis by promoting tumor cell-induced microvascular thrombosis, but clinical data supporting this hypothesis is sparse. CASE REPORTS: Here, we report 2 unusual cases of rapidly progressive solid malignancies (gastric and urothelial carcinoma). In both patients, cancer cell dissemination with diffuse bone marrow involvement was either strongly suggested by leukoerythroblastic changes on peripheral blood smear or directly proven by positive findings on aspiration cytology. Furthermore, laboratory evidence of thrombotic microangiopathy (TMA) and disseminated intravascular coagulation was accompanied by new-onset severe pulmonary hypertension and a hemolytic uremic syndrome-like disorder in the gastric and the urothelial carcinoma patient, respectively. TF-specific procoagulant activity of isolated plasma MPs, as assessed by single-stage clotting assay, was dramatically increased in both patients compared to healthy controls (21- and 55-fold), and primary tumor samples stained strongly positive for TF by immunohistochemistry.
CONCLUSION: TMA was likely caused by TF-triggered tumor cell embolization in both patients. Further clinical evidence is thus provided that TF directly links coagulation activation to cancer cell dissemination.
© 2015 S. Karger GmbH, Freiburg.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26406979     DOI: 10.1159/000433501

Source DB:  PubMed          Journal:  Oncol Res Treat        ISSN: 2296-5270            Impact factor:   2.825


  4 in total

1.  Investigation of the relationship between MTRR A66G, MTR A2756G gene variations and cell anomalies in early diagnosis and progression of bladder cancer.

Authors:  Nevra Alkanli; Arzu Ay; Pinar Koroglu Aydin; Gokhan Cevik
Journal:  Mol Biol Rep       Date:  2022-06-17       Impact factor: 2.742

2.  Insights on pulmonary tumor thrombotic microangiopathy: a seven-patient case series.

Authors:  Rohit Godbole; Rajan Saggar; Alexander Zider; Jamie Betancourt; William D Wallace; Robert D Suh; Nader Kamangar
Journal:  Pulm Circ       Date:  2017-08-25       Impact factor: 3.017

3.  Bladder cancer-derived interleukin-1 converts the vascular endothelium into a pro-inflammatory and pro-coagulatory surface.

Authors:  A John; C Günes; C Bolenz; S Vidal-Y-Sy; A T Bauer; S W Schneider; C Gorzelanny
Journal:  BMC Cancer       Date:  2020-12-02       Impact factor: 4.430

Review 4.  Pancreatic adenocarcinoma, chronic pancreatitis, and MODY-8 diabetes: is bile salt-dependent lipase (or carboxyl ester lipase) at the crossroads of pancreatic pathologies?

Authors:  Dominique Lombardo; Françoise Silvy; Isabelle Crenon; Emmanuelle Martinez; Aurélie Collignon; Evelyne Beraud; Eric Mas
Journal:  Oncotarget       Date:  2017-12-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.